Chia-Jui Yen Selected Research

Ramucirumab

2/2022	Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein.
9/2021	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).
1/2021	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
12/2020	Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study.
8/2020	Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies.
1/2019	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
1/2019	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
3/2018	Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
1/2018	Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].
1/2018	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chia-Jui Yen Research Topics

Disease

61	Neoplasms (Cancer) 06/2022 - 04/2008
44	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 07/2011
13	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021 - 11/2011
11	Adenocarcinoma 06/2022 - 04/2008
10	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2011
7	Stomach Neoplasms (Stomach Cancer) 07/2021 - 01/2014
7	Hypertension (High Blood Pressure) 01/2021 - 07/2015
7	Carcinogenesis 01/2018 - 04/2008
6	Inflammation (Inflammations) 08/2021 - 04/2008
5	Pancreatic Neoplasms (Pancreatic Cancer) 06/2022 - 05/2020
5	Squamous Cell Carcinoma of Head and Neck 01/2021 - 10/2017
5	Liver Neoplasms (Liver Cancer) 01/2020 - 07/2015
4	Disease Progression 12/2021 - 07/2015
4	Fatigue 12/2021 - 12/2014
4	Neutropenia 10/2020 - 03/2016
4	Breast Neoplasms (Breast Cancer) 09/2020 - 08/2008
4	Pain (Aches) 04/2020 - 01/2017
4	Nausea 12/2019 - 12/2014
4	Infections 07/2015 - 02/2004
3	Nasopharyngeal Carcinoma 01/2022 - 10/2014
3	Fibrosis (Cirrhosis) 12/2021 - 02/2017
3	Cancer Pain 04/2020 - 01/2017
3	Vomiting 12/2019 - 12/2014
3	Diarrhea 12/2019 - 12/2014
3	Liver Diseases (Liver Disease) 01/2019 - 07/2015
3	Exanthema (Rash) 05/2018 - 12/2014
3	Chronic Hepatitis B 05/2016 - 01/2012
2	Hepatitis C 12/2021 - 02/2004
2	Pruritus (Itching) 12/2021 - 10/2017
2	Hemorrhage 01/2021 - 12/2020
2	Febrile Neutropenia 12/2020 - 03/2018
2	Asthenia 08/2020 - 07/2015
2	Ascites 08/2020 - 07/2015
2	Obesity 05/2020 - 11/2008
2	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 08/2019
2	Leukopenia 03/2018 - 03/2016
2	Carcinoma (Carcinomatosis) 01/2017 - 12/2016
2	Hypoxia (Hypoxemia) 02/2016 - 10/2015
2	Hypersensitivity (Allergy) 01/2016 - 01/2013
2	Tuberous Sclerosis (Bourneville's Disease) 01/2012 - 04/2008
2	Lung Neoplasms (Lung Cancer) 08/2011 - 01/2011

Drug/Important Bio-Agent (IBA)

16	RamucirumabIBA 02/2022 - 07/2015
12	Biomarkers (Surrogate Marker)IBA 06/2022 - 07/2011
11	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 08/2008
8	Fluorouracil (Carac)FDA LinkGeneric 06/2022 - 08/2011
8	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2022 - 02/2015
7	Leucovorin (Folinic Acid)FDA Link 06/2022 - 01/2014
7	Paclitaxel (Taxol)FDA LinkGeneric 08/2021 - 08/2008
6	Irinotecan (Camptosar)FDA LinkGeneric 06/2022 - 01/2020
6	Gemcitabine FDA Link 01/2022 - 01/2020
6	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2014
6	Messenger RNA (mRNA)IBA 01/2020 - 01/2013
5	PlatinumIBA 12/2021 - 03/2016
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2008
5	Pharmaceutical PreparationsIBA 12/2019 - 11/2011
4	BilirubinIBA 09/2021 - 07/2015
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 12/2014
4	Analgesics (Analgesic Drugs)IBA 04/2020 - 01/2017
4	CytokinesIBA 06/2019 - 11/2008
4	MicroRNAs (MicroRNA)IBA 01/2017 - 04/2013
4	Phosphotransferases (Kinase)IBA 04/2013 - 04/2008
3	Membrane Proteins (Integral Membrane Proteins)IBA 05/2022 - 07/2015
3	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 07/2015
3	NivolumabIBA 10/2020 - 10/2017
3	Fetal Proteins (Fetoprotein)IBA 01/2019 - 01/2014
3	ErbB Receptors (EGF Receptor)IBA 01/2016 - 04/2013
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2015 - 08/2011
3	TOR Serine-Threonine KinasesIBA 01/2012 - 04/2008
3	Ribosomal Protein S6 Kinases (S6 Kinase)IBA 01/2012 - 04/2008
2	spartalizumabIBA 06/2022 - 12/2021
2	toripalimabIBA 01/2022 - 01/2021
2	Bevacizumab (Avastin)FDA Link 01/2022 - 08/2011
2	ADI PEG20IBA 12/2021 - 01/2021
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2021 - 01/2019
2	AlbuminsIBA 09/2021 - 04/2021
2	pembrolizumabIBA 06/2021 - 01/2021
2	Cetuximab (Erbitux)FDA Link 01/2021 - 01/2019
2	Metformin (Glucophage)FDA LinkGeneric 09/2020 - 01/2020
2	Monoclonal AntibodiesIBA 03/2020 - 01/2016
2	CCAAT-Enhancer-Binding Protein-deltaIBA 01/2020 - 11/2015
2	Biological ProductsIBA 01/2020 - 01/2016
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2011
2	Cadherins (E-Cadherin)IBA 08/2018 - 01/2014
2	nintedanibIBA 05/2018 - 01/2017
2	Sirolimus (Rapamycin)FDA Link 01/2018 - 04/2008
2	Surface Antigens (Surface Antigen)IBA 01/2018 - 02/2013
2	codrituzumabIBA 02/2017 - 01/2016
2	SERPIN-B5 (maspin)IBA 08/2016 - 09/2015
2	hepatitis B virus X proteinIBA 01/2016 - 01/2012
2	Lapatinib (GW572016)FDA Link 01/2016 - 04/2013
2	Oncogene Proteins (Oncogene Protein)IBA 07/2015 - 02/2013
2	Polysaccharides (Glycans)IBA 01/2014 - 01/2012
1	roblitinibIBA 06/2022

Therapy/Procedure

25	Therapeutics 12/2021 - 02/2004
14	Drug Therapy (Chemotherapy) 01/2022 - 08/2011
5	Oral Hygiene (Dental Hygiene) 05/2020 - 10/2013
4	Neoadjuvant Therapy 01/2022 - 10/2014
3	Pain Management 04/2020 - 05/2019
2	Chemoradiotherapy 03/2015 - 10/2014
2	Hepatectomy 01/2013 - 07/2011